<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83276">
  <stage>Registered</stage>
  <submitdate>16/10/2008</submitdate>
  <approvaldate>17/12/2008</approvaldate>
  <actrnumber>ACTRN12608000639325</actrnumber>
  <trial_identification>
    <studytitle>Multicentre clinical study with early treatment intensification in patients with high-risk Hodgkin Lymphoma, identified as 18-F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) scan positive after two conventional Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) courses</studytitle>
    <scientifictitle>This study  evaluates the 3-year progression free survival (PFS) by using Positron Emission Tomography (PET)-adapted chemotherapy in advanced Hodgkin Lymphoma</scientifictitle>
    <utrn />
    <trialacronym>HD0607</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Hodgkin Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All participants receive the initial therapy that consists in 2 courses of Doxorubicin (25 mg/m2 intravenous (iv) days 1,15), Bleomycin (10,000 units/m2 iv days 1,15), Vinblastine (6 mg/m2 iv days 1,15), Dacarbazine (375 mg/m2 iv days 1,15) (ABVD). After this two cycles (cycle repeats every 28 days) a early PET will be performed. If PET is positive the participants will be randomized to 4 (cycles repeat every 21 days) escalated Bleomycin (10 mg/m2/endovenous (ev)/day,  day 8), Etoposide (200 mg/m2/ev/day, days 1-3), Doxorubicin  (35 mg/m2/ev/day, day 1), Cyclophosphamide (1250 mg/m2/ev/day, day 1), Vincristine (1,4 mg/m2/ev/day, day 8), Procarbazine (100 mg/m2/b.m./day, days 1-7), Prednisone (40 mg/m2/b.m./day, days 1-14),(BEACOPPesc) or escalated Bleomycin (10 mg/m2/ev/day, day 8), Etoposide (200 mg/m2/ev/day, days 1-3), Doxorubicin  (35 mg/m2/ev/day, day 1), Cyclophosphamide (1250 mg/m2/ev/day, day 1), Vincristine (1,4 mg/m2/ev/day, day 8), Procarbazine (100 mg/m2/b.m./day, days 1-7), Prednisone (40 mg/m2/b.m./die 1°-14°), Rituximab (375 mg/m2/ev/day, day 1) (R-BEACOPPesc). After participants will be received another PET.</interventions>
    <comparator>After two conventional courses of Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) patients who have a negative Positron Emission Tomography (PET) scan will be treated with  other 4 courses of Doxorubicin (25 mg/m2 iv days 1,15), Bleomycin (10,000 units/m2 iv days 1,15), Vinblastine (6 mg/m2 iv days 1,15), Dacarbazine (375 mg/m2 iv days 1,15) (ABVD) Cycles repeat every 28 days. After participants will be received another PET.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>3-year progression free survival (PFS) evaluated with a follow-up Case Report Form (CRF) each 6 months for 3 years</outcome>
      <timepoint>every 6 months for 3 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>3-year event free survival (EFS) of all the registered patients whatever the treatment assigned. Events are deaths from any cause, disease progression, secondary cancer, late serious treatment-related events.
- Feasibility of the program for the entire population of advanced-stage Hodgkin Lymphoma patients admitted to Gruppo Italiano Terapia Innovativa nei Linfomi (GITIL) institutions evaluated with a follow-up Case Report Form (CRF) each 6 months for 3 years</outcome>
      <timepoint>every 6 months for 3 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Patients with advanced classical Hodgkin Lymphoma according to the World Health Organization classification
-Aged 18-60
-Not previously treated
-Stages IIB to IV B 
-All International Prognostic Score (IPS) prognostic groups
-Patients who have signed an informed consent form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-Patients aged more than 60.
-Concomitant or previously treated neoplastic disorder less than 5 year before the diagnosis of Hodgkins lymphoma.
-Psychiatric disorders
-Uncontrolled infectious disease
-Impaired cardiac (Ejection Fraction (EF) &lt; 50%) , renal (creatinine clearance &lt; 60 ml/m)
-Human Immunodeficiency Virus (HIV) Hepatitis B Virus  Deoxyribonucleic Acid(HBV DNA), Hepatitis C Virus Ribonucleic Acid (HCV RNA) positive markers
-Pregnancy and lactation     
-Patients with uncompensated diabetes mellitus and fasting glucose levels over 200 mg/dl</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer</concealment>
    <sequence>Stratified allocation. Factors such as centre, age gender or previous treatment are used for the stratification.
Simple randomisation by using a randomisation table created by a computer software (i.e., computerised sequence generation)</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>24/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Gruppo Italiano Terapie Innovative nei Linfomi (GITIL)</primarysponsorname>
    <primarysponsoraddress>Via Schiaparelli, 23
12100 Cuneo</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Gruppo Italiano Terapia Innovativa nei Linfomi</fundingname>
      <fundingaddress>Via Schiaparelli, 23
12100 Cuneo</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In the present study, after two courses of standard Doxorubicin Bleomycin Vinblastine Dacarbazine (ABVD) treatment patients will be evaluated for chemosensitivity by Positron Emission Tomography (PET): patients with a positive scan will be addressed to a more aggressive therapy with either escalated Bleomycin Etoposide Doxorubicin Cyclophosphamide Vincristine Procarbazine Prednisone (BEACOPP) or escalated Rituximab-Bleomycin Etoposide Doxorubicin Cyclophosphamide Vincristine Procarbazine Prednisone (R-BEACOPP); patients with a negative scan will continue the standard therapy.</summary>
    <trialwebsite>https://heart.negrisud.it/HD/</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comitato Etico Interaziendale dell'ASO Sante Croce e Carle di Cuneo</ethicname>
      <ethicaddress>Via M. Zovetto, 18
12100 Cuneo</ethicaddress>
      <ethicapprovaldate>16/05/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mariangela Saggese</name>
      <address>Via Nazionale 8/A
66030 Santa Maria Imbaro (Chieti)</address>
      <phone>0039-0872/570322</phone>
      <fax>0039-0872/570206</fax>
      <email>saggese@negrisud.it , hd0607@negrisud.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mariangela Saggese</name>
      <address>Via Nazionale 8/A
66030 Santa Maria Imbaro (Chieti)</address>
      <phone>0039-0872/570322</phone>
      <fax>0039-0872/570206</fax>
      <email>saggese@negrisud.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mariangela Saggese</name>
      <address>Via Nazionale 8/A
66030 Santa Maria Imbaro (Chieti)</address>
      <phone>0039-0872/570322</phone>
      <fax>0039-0872/570206</fax>
      <email>saggese@negrisud.it , hd0607@negrisud.it</email>
      <country>Italy</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>